pH-D Feminine Health announced on August 12, 2025, that it has initiated the first randomized, placebo-controlled, double-blinded Phase 3 clinical trial cleared by the U.S. Food and Drug Administration to clinically validate boric acid suppositories as a potential treatment for yeast infections. The pivotal study represents a critical milestone in bringing clinical clarity to boric acid suppositories and aims to support submission of a New Drug Application.
Addressing Clinical Evidence Gap
"By sponsoring this pivotal clinical trial, we're taking the lead to generate the scientific evidence women deserve," said Deeannah Seymour, co-founder and CEO of pH-D Feminine Health. "This trial marks a decisive step toward providing boric acid for therapeutic use to women through rigorous research and regulatory alignment."
The study addresses what experts describe as a decades-long gap in clinical evidence for boric acid suppositories. "Evaluating boric acid suppositories for therapeutic use addresses a decades-long gap in clinical evidence and could prove groundbreaking for women's health," noted Aparna D. Shah, MD, FACOG, board certified in OB/GYN and urogynecology.
Current Clinical Recognition
The American College of Obstetricians and Gynecologists recognizes boric acid as a second-line option in its clinical guidelines for managing vaginitis in non-pregnant women. The Centers for Disease Control and Prevention also supports boric acid efficacy in managing recurrent Vulvovaginal candidiasis with 600 mg of boric acid suppositories administered vaginally in the same population.
Study Design and Timeline
The rigorous Phase 3 study design focuses on the impact of locally administered boric acid for the treatment of vaginal yeast infections in women. According to Dr. Shah, "We expect this research on safety and efficacy to help further demonstrate the therapeutic potential of boric acid as a locally administered drug."
Enrollment for the Phase 3 study has begun at nearly 20 trial sites nationwide. The study is anticipated to be completed in June 2026, with details available on ClinicalTrials.Gov.
Company Background
Female owned and operated since 2014, pH-D Feminine Health has pioneered boric acid suppository products. The pH-D boric acid vaginal suppository is an investigational product and has not been approved by the U.S. Food and Drug Administration for the treatment, cure, or prevention of vulvovaginal candidiasis. The company's retail products continue to be available online and nationwide.
Co-founder Deeannah Seymour emphasized the company's mission: "Our mission has always been clear: advance the science, honor the data, and make affordable, accessible solutions available to every woman who needs them." Seymour is a Forbes 50 Over 50: Innovation 2025 and an INC. 5000 recipient.
